Follow this innovation
[ via 
] [?]
Lodamin for treating uveitis and other autoimmune diseases
Children's Hospital Boston
posted on 12/09/2011
TNP-470 was a promising drug in oncology development but Phase II trials were interrupted because of reversible neurotoxicity. Also, the drug had poor oral availability and a short half-life. || Dr. Ofra Benny-Ratsaby and Dr. Judah Folkman developed Lodamin, a non-toxic derivative of TNP-470. Lodamin is a conjugate of TNP-470 to a PEG-PLA copolymer. It forms micelles with TNP-470 at its core allowing for oral availability and for delivery to the tumor where the drug is slowly released. Lodamin exhibited anti-angiogenic activity in vivo and inhibited primary tumor growth in mouse models of melanoma, lung, breast, brain and ovarian cancers by more than 80%, without neurotoxicity or other adverse events. || Dr. Benny and Dr. Robert D'Amato have found that Lodamin is also a potent inhibitor of a specific population of T helper cells: Th17. This cell population is a key mediator in chronic inflammatory diseases and promotes many autoimmune and chronic inflammatory conditions. Lodamin ameliorated clinical scores in animal models of Uveitis - Experimental Autoimmune Uveoretinitis (EAU).||
File Number: CMCC 1855
Other Information: *Investigator(s)*
Robert D'Amato
*Contact*
Maude Tessier, Maude.Tessier@childrens.harvard.edu
This innovation currently is not available for online licensing. Please contact David Altman at Children's Hospital Boston for more information.
request more info
ProfileFind more innovations
